Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001849 · ClinicalTrials.gov registry record · Phase 2
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
A Phase 2 study of Cushing Syndrome and Endocrine Disease, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
- 1
- Study location
NCT00001849: Completed Phase 2 study of Cushing Syndrome and Endocrine Disease, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
NCT00001849 is a Phase 2 study of Cushing Syndrome and Endocrine Disease that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 95 participants, below the 170-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001849, a Phase 2 study of Cushing Syndrome and Endocrine Disease, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
Cushing Syndrome is an endocrine disorder causing an over production of the hormone cortisol. Cortisol is produced in the adrenal gland as a response to the production of corticotropin (ACTH) in the pituitary gland. Between 10% and 20% of patients with hypercortisolism (Cushing Syndrome) have ectopic production of the hormone ACTH. Meaning, the hormone is not being released from the normal site, the pituitary gland. In many cases the ectopic ACTH is being produced by a tumor of the lung, thymus, or pancreas. However, in approximately 50% of these patients the source of the ACTH cannot be found even with the use of extensive imaging studies such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and nuclear scans (111-indium pentetreotide). The ability of these tests to locate the source of the hormone production is dependent on the changes of anatomy and / or the dose and adequate uptake of the radioactive agent. The inability to detect the source of ectopic ACTH production often results in unnecessary pituitary surgery or irradiation. Unlike the previously described tests, positron emission tomography (PET scan) has the ability to detect pathologic tissue based on physiologic and biochemical processes within the abnormal tissue. This study will test whether fluorine-18-fluorodeoxyglucose (FDG), fluorine-18-dihydroxyphenylalanine (F-DOPA) or use of a higher dose of 111-indium pentetreotide can be used to successfully localize the source of ectopic ACTH production.
Primary Outcome
The percentage of patients in whom imaging correctly identified an ACTH-secreting non-pituitary tumor within six months of resection or in which imaging identified a recurrence at a site of previous resection.
Conditions Studied
Interventions
- DEVICE MRI
- DRUG 18F-DOPA
- DRUG Pentetreotide
- DEVICE CT scan
- DRUG 18-FDG
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 1999-05-20 |
| Est. Completion | 2019-04-26 |
| Phase | Phase 2 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
What the finished NCT00001849 record still lists
NCT00001849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 170-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (44% lower).
The record links to 2 conditions, with Cushing Syndrome appearing as the primary indexed condition, and to 5 interventions - of which MRI is the first listed.
NCT00001849 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00001849 about?
NCT00001849 is a clinical study titled "New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome". Cushing Syndrome is an endocrine disorder causing an over production of the hormone cortisol. Cortisol is produced in the adrenal gland as a response to the production of corticotropin (ACTH) in the pituitary gland. Between 10% and 20% of patients with hypercortisolism (Cushing Syndrome) have ectop...
What is the current status of trial NCT00001849?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 1999-05-20. Estimated completion is 2019-04-26.
What conditions does trial NCT00001849 study?
This clinical trial studies the following conditions: Cushing Syndrome, Endocrine Disease.
What interventions are being tested in trial NCT00001849?
The interventions under investigation include: MRI (DEVICE), 18F-DOPA (DRUG), Pentetreotide (DRUG), CT scan (DEVICE), 18-FDG (DRUG).
Who is sponsoring clinical trial NCT00001849?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001849 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001849's enrollment target sits among peer trials
95 6th of 9 higher than 4 of 9 other Cushing Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cushing Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
RECRUITING · Phase 2
-
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
RECRUITING · Phase 2
-
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
RECRUITING · Phase 1
-
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
RECRUITING
-
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI